RP
CRL icon

Riverbridge Partners’s Charles River Laboratories CRL Stock Holding History

Riverbridge Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.9M Sell
56,703
-7,085
-11% -$1.26M 0.36% 65
2026
Q1 		$11M Sell
63,788
-35,540
-36% -$6.59M 0.27% 80
2025
Q4 		$19.8M Sell
99,328
-25,976
-21% -$4.71M 0.37% 72
2025
Q3 		$19.6M Sell
125,304
-8,323
-6% -$1.32M 0.33% 76
2025
Q2 		$20.3M Sell
133,627
-89,107
-40% -$11.9M 0.33% 81
2025
Q1 		$33.5M Sell
222,734
-16,654
-7% -$2.79M 0.54% 66
2024
Q4 		$44.2M Sell
239,388
-27,059
-10% -$5.21M 0.6% 61
2024
Q3 		$52.5M Sell
266,447
-22,825
-8% -$4.74M 0.7% 54
2024
Q2 		$59.8M Sell
289,272
-14,506
-5% -$3.29M 0.81% 47
2024
Q1 		$82.3M Buy
303,778
+3,088
+1% +$737K 1% 38
2023
Q4 		$71.1M Sell
300,690
-14,368
-5% -$2.83M 0.89% 43
2023
Q3 		$61.7M Sell
315,058
-6,122
-2% -$1.26M 0.84% 43
2023
Q2 		$67.5M Buy
321,180
+22,186
+7% +$4.41M 0.85% 45
2023
Q1 		$60.3M Sell
298,994
-1,814
-0.6% -$411K 0.85% 44
2022
Q4 		$65.5M Sell
300,808
-18,412
-6% -$4.02M 0.98% 34
2022
Q3 		$62.8M Buy
319,220
+87,669
+38% +$18.9M 0.93% 38
2022
Q2 		$49.5M Sell
231,551
-27,470
-11% -$6.71M 0.79% 47
2022
Q1 		$73.6M Buy
259,021
+88,183
+52% +$27.2M 0.83% 45
2021
Q4 		$64.4M Buy
170,838
+5,553
+3% +$2.16M 0.64% 54
2021
Q3 		$68.2M Sell
165,285
-751
-0.5% -$312K 0.68% 57
2021
Q2 		$61.4M Buy
166,036
+10,657
+7% +$3.56M 0.62% 57
2021
Q1 		$45M Buy
+155,379
New +$43.2M 0.51% 65

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Riverbridge Partners's CRL Position: Q2 2026 in Review

Riverbridge Partners reduced its Charles River Laboratories (CRL) stake by 11% in Q2 2026, selling an estimated $1.26M and leaving 56,703 shares worth $12.9M. The position accounts for 0.36% of the portfolio, ranked #65.

Riverbridge Partners first reported a position in CRL in Q1 2021 and has held it in 22 quarters since. The position peaked at $82.3M in Q1 2024. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Riverbridge Partners held 56,703 shares of Charles River Laboratories worth $12.9M as of Q2 2026.
  • Riverbridge Partners sold 7,085 Charles River Laboratories shares in Q2 2026, an estimated $1.26M.
  • Charles River Laboratories made up 0.36% of Riverbridge Partners's portfolio in Q2 2026, its #65 holding.
  • Riverbridge Partners first reported a position in Charles River Laboratories in Q1 2021 and has held it in 22 quarters since.
  • Riverbridge Partners's Charles River Laboratories position peaked at $82.3M in Q1 2024.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Riverbridge Partners's 13F filing for Q2 2026, filed 13 Jul 2026.